600 related articles for article (PubMed ID: 11331613)
41. Structural bioinformatics mutation analysis reveals genotype-phenotype correlations in von Hippel-Lindau disease and suggests molecular mechanisms of tumorigenesis.
Forman JR; Worth CL; Bickerton GR; Eisen TG; Blundell TL
Proteins; 2009 Oct; 77(1):84-96. PubMed ID: 19408298
[TBL] [Abstract][Full Text] [Related]
42. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation.
Jaakkola P; Mole DR; Tian YM; Wilson MI; Gielbert J; Gaskell SJ; von Kriegsheim A; Hebestreit HF; Mukherji M; Schofield CJ; Maxwell PH; Pugh CW; Ratcliffe PJ
Science; 2001 Apr; 292(5516):468-72. PubMed ID: 11292861
[TBL] [Abstract][Full Text] [Related]
43. Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas.
Na X; Wu G; Ryan CK; Schoen SR; di'Santagnese PA; Messing EM
J Urol; 2003 Aug; 170(2 Pt 1):588-92. PubMed ID: 12853836
[TBL] [Abstract][Full Text] [Related]
44. Identification of membrane type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2 alpha in von Hippel-Lindau renal cell carcinoma.
Petrella BL; Lohi J; Brinckerhoff CE
Oncogene; 2005 Feb; 24(6):1043-52. PubMed ID: 15592504
[TBL] [Abstract][Full Text] [Related]
45. von Hippel-Lindau syndrome.
Chou A; Toon C; Pickett J; Gill AJ
Front Horm Res; 2013; 41():30-49. PubMed ID: 23652669
[TBL] [Abstract][Full Text] [Related]
46. The role of von Hippel-Lindau tumor suppressor protein and hypoxia in renal clear cell carcinoma.
Sufan RI; Jewett MA; Ohh M
Am J Physiol Renal Physiol; 2004 Jul; 287(1):F1-6. PubMed ID: 15180922
[TBL] [Abstract][Full Text] [Related]
47. Von Hippel-Lindau disease and sporadic renal cell carcinoma.
Zbar B
Cancer Surv; 1995; 25():219-32. PubMed ID: 8718521
[TBL] [Abstract][Full Text] [Related]
48. VHL takes HIF's breath away.
Krek W
Nat Cell Biol; 2000 Jul; 2(7):E121-3. PubMed ID: 10878820
[TBL] [Abstract][Full Text] [Related]
49. The N131S mutation in the von Hippel-Lindau gene in a Japanese family with pheochromocytoma and hemangioblastomas.
Imanaka M; Iida K; Takahashi K; Tsuji K; Nishizawa H; Fukuoka H; Takeno R; Takahashi Y; Okimura Y; Kaji H; Chihara K
Endocr J; 2006 Dec; 53(6):819-27. PubMed ID: 17001110
[TBL] [Abstract][Full Text] [Related]
50. Identification of the von Hippel-lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex.
Iwai K; Yamanaka K; Kamura T; Minato N; Conaway RC; Conaway JW; Klausner RD; Pause A
Proc Natl Acad Sci U S A; 1999 Oct; 96(22):12436-41. PubMed ID: 10535940
[TBL] [Abstract][Full Text] [Related]
51. Identification of residues critical for regulation of protein stability and the transactivation function of the hypoxia-inducible factor-1alpha by the von Hippel-Lindau tumor suppressor gene product.
Pereira T; Zheng X; Ruas JL; Tanimoto K; Poellinger L
J Biol Chem; 2003 Feb; 278(9):6816-23. PubMed ID: 12468553
[TBL] [Abstract][Full Text] [Related]
52. The HIF pathway: implications for patterns of gene expression in cancer.
Wykoff CC; Pugh CW; Harris AL; Maxwell PH; Ratcliffe PJ
Novartis Found Symp; 2001; 240():212-25; discussion 225-31. PubMed ID: 11727931
[TBL] [Abstract][Full Text] [Related]
53. Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C.
Kibel A; Iliopoulos O; DeCaprio JA; Kaelin WG
Science; 1995 Sep; 269(5229):1444-6. PubMed ID: 7660130
[TBL] [Abstract][Full Text] [Related]
54. Dynamic, site-specific interaction of hypoxia-inducible factor-1alpha with the von Hippel-Lindau tumor suppressor protein.
Yu F; White SB; Zhao Q; Lee FS
Cancer Res; 2001 May; 61(10):4136-42. PubMed ID: 11358837
[TBL] [Abstract][Full Text] [Related]
55. RSUME inhibits VHL and regulates its tumor suppressor function.
Gerez J; Tedesco L; Bonfiglio JJ; Fuertes M; Barontini M; Silberstein S; Wu Y; Renner U; Páez-Pereda M; Holsboer F; Stalla GK; Arzt E
Oncogene; 2015 Sep; 34(37):4855-66. PubMed ID: 25500545
[TBL] [Abstract][Full Text] [Related]
56. Protective function of von Hippel-Lindau protein against impaired protein processing in renal carcinoma cells.
Gorospe M; Egan JM; Zbar B; Lerman M; Geil L; Kuzmin I; Holbrook NJ
Mol Cell Biol; 1999 Feb; 19(2):1289-300. PubMed ID: 9891063
[TBL] [Abstract][Full Text] [Related]
57. Clusterin is a secreted marker for a hypoxia-inducible factor-independent function of the von Hippel-Lindau tumor suppressor protein.
Nakamura E; Abreu-e-Lima P; Awakura Y; Inoue T; Kamoto T; Ogawa O; Kotani H; Manabe T; Zhang GJ; Kondo K; Nosé V; Kaelin WG
Am J Pathol; 2006 Feb; 168(2):574-84. PubMed ID: 16436671
[TBL] [Abstract][Full Text] [Related]
58. Regulation of HIF by the von Hippel-Lindau tumour suppressor: implications for cellular oxygen sensing.
Mole DR; Maxwell PH; Pugh CW; Ratcliffe PJ
IUBMB Life; 2001 Jul; 52(1-2):43-7. PubMed ID: 11795592
[TBL] [Abstract][Full Text] [Related]
59. Expression of fibronectin and HIF-1alpha in renal cell carcinomas: relationship to von Hippel-Lindau gene inactivation.
He Z; Liu S; Guo M; Mao J; Hughson MD
Cancer Genet Cytogenet; 2004 Jul; 152(2):89-94. PubMed ID: 15262424
[TBL] [Abstract][Full Text] [Related]
60. Genotype-phenotype analysis of von Hippel-Lindau syndrome in Korean families: HIF-α binding site missense mutations elevate age-specific risk for CNS hemangioblastoma.
Lee JS; Lee JH; Lee KE; Kim JH; Hong JM; Ra EK; Seo SH; Lee SJ; Kim MJ; Park SS; Seong MW
BMC Med Genet; 2016 Jul; 17(1):48. PubMed ID: 27439424
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
